ILMN250117P280000
- 95.00
- 0.000.00%
Illumina Newsroom
Illumina Partners NVIDIA for Genomic Advancements, ILMN Stock Climbs
Grail 2024 Revenue Guidance Range Above Consensus
BofA Securities Maintains Illumina(ILMN.US) With Sell Rating, Maintains Target Price $120
Bernstein Maintains Illumina(ILMN.US) With Hold Rating
Sector Update: Health Care Stocks Fall Tuesday Afternoon
Express News | Illumina Shares Reverse Premarket Losses, Now up 2.5%
Illumina, Nvidia Collaborate to Decode Biology and Propel Precision Health
Illumina Announces Preliminary Financials For Q4 2024 With $1.10B Revenue, 2024 Revenue At $4.33B, GAAP EPS $5.65-$5.67; Non-GAAP EPS $4.12-$4.14; Sees 2025 Revenue Outlook Of $4.28B-$4.4B, Non-GAAP Margin 23%, EPS Growth 10%
Nvidia Eyes $1 Billion In Healthcare AI Revenue: Is This The Next Growth Frontier?
Express News | Illumina Shares Fall 3.6% Premarket After Prelim Q4 Results
Express News | Illumina Inc Q4 Shr View $0.91, Rev View $1.07 Bln -- LSEG IBES Data
Illumina Sees 4Q Rev $1.1B >ILMN
Illumina Sees 4Q EPS 77c-EPS 79c >ILMN
Express News | Illumina: For FY 2025, Expect Constant Currency Revenue Growth in Low Single Digits (Reported Revenue in Range of About $4.28 Bln to $4.4 Bln)
Express News | Illumina Inc: Preliminary Non-Gaap Diluted EPS of Approximately $0.91 - $0.93 for Q4 2024
Express News | Illumina Q4 Revenue USD 1,100 Million Vs. IBES Estimate USD 1,072 Million
Express News | Illumina Outlook FY Adjusted Operating Margin 23%
Express News | Illumina Q4 EBIT Margin 16.7%
Express News | Illumina Q4 Adjusted EBIT Margin 1.5%
Press Release: Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2024 and Provides Preliminary Outlook for Fiscal Year 2025